XNW34017 / Evopoint - LARVOL DELTA

Discovery and characterization of XNW34017, a first-in-class, orally bioavailable, and brain-penetrant AURKA-MYC degrader (AACR 2026) - "Observed toxicities were consistent with on-target degradation of AURKA, with no unexpected safety risk observed. Together, our MOA and preclinical studies support the advancement of XNW34017 into clinical development for MYC-driven malignancies."

Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • AURKA • MYC • MYCL • MYCN